With increasing numbers of patients needing intensive care or who are immunosuppressed,
infections caused by moulds other than Aspergillus spp or Mucorales are increasing …

Antifungal resistance represents a major clinical challenge to clinicians responsible for
treating invasive fungal infections due to the limited arsenal of systemically available …

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

In humans, microbial cells (including bacteria, archaea, and fungi) greatly outnumber host
cells. Candida albicans is the most prevalent fungal species of the human microbiota; this …

Invasive fungal infections (IFI) are an emerging problem worldwide with invasive candidiasis
and candidemia responsible for the majority of cases. This is predominantly driven by the …

Chromoblastomycosis (CBM), also known as chromomycosis, is one of the most prevalent
implantation fungal infections, being the most common of the gamut of mycoses caused by …

Fungal infections are becoming more frequent because of expansion of at-risk populations
and the use of treatment modalities that permit longer survival of these patients. Because …

Assessment of the global burden and epidemiologic trends of fungal diseases is critical to
prioritizing prevention strategies, diagnostic modalities, and therapeutic interventions. The …

Abstract Species of Scedosporium and Lomentospora are considered as emerging
opportunists, affecting immunosuppressed and otherwise debilitated patients, although …

Mycoses summarized in the hyalohyphomycosis group are heterogeneous, defined by the
presence of hyaline (non‐dematiaceous) hyphae. The number of organisms implicated in …